ood morning, one and all. Damian Garde here, filling in for Ed Silverman on what looks like a dreary day, at least weather-wise, on Pharmalot’s satellite campus to the north. Here, please find your as-expected handful of headlines to begin what we hope will be a day as productive as it is painless. And if you hear something particularly head-turning along the way, do drop us a line.
Johnson & Johnson (JNJ) is breaking the law to protect its blockbuster anti-inflammatory Remicade, according to Pfizer, which is suing in hopes of improving sales for its biosimilar. Pfizer (PFE) argues that J&J is using rebates and contracts to illegally maintain a monopoly, pulling strings with pharmacy benefit managers to keep Inflectra, the biosimilar, from getting the insurance coverage it needs to gain market share.